4'- (4,4- difluoro- 5- (2- oxo- 2- (4- piperidinopiperidino)ethylidene)- 2,3,4,5- tetrahydro- 1H- 1- benzoazepine- 1- carbonyl)- 2- methyl- 3- furanilide

Subscribe to Selected New Research on 4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide

4 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: a vasopressin V(1A) receptor antagonist; structure in first source

Also Known As:

(Z)-4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide hemifumarate; YM 218; YM-218; YM218

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Piperidines: 7

4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide: 4

2-Ring Heterocyclic Compounds

Benzazepines: 2

4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide: 4

Experts

1.	Shibasaki, Masayuki: 1 article (06/2007)
2.	Tahara, Atsuo: 1 article (06/2007)
3.	Tomura, Yuichi: 1 article (06/2007)
4.	Yatsu, Takeyuki: 1 article (06/2007)
5.	Suzuki, Takeshi: 1 article (06/2007)
6.	Tsukada, Junko: 1 article (06/2007)

Related Diseases

1.	Hyperplasia 06/01/2007 - "YM218 potently prevented AVP-induced hyperplasia and hypertrophy of these cells" 01/01/2006 - "Conversely, YM218 potently suppressed [Ca(2+)](i) elevation, activation of MAP kinase and hyperplasia induced by AVP" 06/01/2007 - "Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy." 05/24/2006 - "YM218 showed high affinity for vasopressin V(1A) receptors, exhibiting a K(i) value of 0.18 nM. Vasopressin concentration-dependently increased intracellular Ca(2+) levels and induced hyperplasia and hypertrophy in cultured mesangial cells, YM218 potently inhibited these vasopressin-induced responses" Get all the results and reference details, order at left...
2.	Hypertrophy 06/01/2007 - "YM218 potently prevented AVP-induced hyperplasia and hypertrophy of these cells" 06/01/2007 - "Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy." 05/24/2006 - "YM218 showed high affinity for vasopressin V(1A) receptors, exhibiting a K(i) value of 0.18 nM. Vasopressin concentration-dependently increased intracellular Ca(2+) levels and induced hyperplasia and hypertrophy in cultured mesangial cells, YM218 potently inhibited these vasopressin-induced responses" Get all the results and reference details, order at left...
3.	Proteinuria 12/01/2006 - "To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I)" Get all the results and reference details, order at left...
4.	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 12/01/2006 - "To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I)" Get all the results and reference details, order at left...
4 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Vasopressins (Vasopressin)
2.	Phosphotransferases (Kinase)
3.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Nephrectomy
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>